Header cover image

Danish (OMX) Clinical Research and Equipment Industry Analysis

UpdatedJul 16, 2024
DataAggregated Company Financials
Companies2
  • 7D-7.0%
  • 3M70.7%
  • 1Y84.1%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.6%, driven by a pullback from Gubra of 12%. On the other hand ChemoMetec is actually up 6.3%. Over the past 12 months, the industry was up 80%. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the Danish Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 16 Jul 2024DKK 16.9bDKK 606.5mDKK 99.3m45.5x170.6x27.9x
Thu, 13 Jun 2024DKK 11.2bDKK 606.5mDKK 99.3m39.9x112.6x18.4x
Sat, 11 May 2024DKK 10.9bDKK 606.5mDKK 99.3m37.9x110.3x18.1x
Mon, 08 Apr 2024DKK 11.3bDKK 606.5mDKK 99.3m45.6x113.9x18.6x
Wed, 06 Mar 2024DKK 12.6bDKK 606.5mDKK 99.3m62.4x126.6x20.7x
Fri, 02 Feb 2024DKK 8.4bDKK 647.9mDKK 171.7m35.4x48.8x12.9x
Sun, 31 Dec 2023DKK 8.8bDKK 647.9mDKK 171.7m37.8x51.2x13.6x
Tue, 28 Nov 2023DKK 8.2bDKK 647.9mDKK 171.7m35.2x47.8x12.7x
Thu, 26 Oct 2023DKK 6.0bDKK 647.9mDKK 171.7m25.2x35.2x9.3x
Sat, 23 Sep 2023DKK 7.6bDKK 647.9mDKK 171.7m32.8x44.3x11.7x
Mon, 21 Aug 2023DKK 8.9bDKK 660.6mDKK 184.0m213.1x48.2x13.4x
Wed, 19 Jul 2023DKK 9.3bDKK 660.6mDKK 184.0m197.2x50.5x14.1x
Fri, 16 Jun 2023DKK 10.2bDKK 660.6mDKK 184.0m202.6x55.5x15.5x
Sun, 14 May 2023DKK 8.8bDKK 660.6mDKK 184.0m204.7x47.6x13.2x
Tue, 11 Apr 2023DKK 6.5bDKK 461.2mDKK 179.7m36.3x36.3x14.1x
Thu, 09 Mar 2023DKK 7.4bDKK 461.2mDKK 179.7m40.9x40.9x15.9x
Sat, 04 Feb 2023DKK 11.3bDKK 428.4mDKK 159.5m70.8x70.8x26.3x
Mon, 02 Jan 2023DKK 12.0bDKK 428.4mDKK 159.5m75.4x75.4x28.1x
Wed, 30 Nov 2022DKK 14.5bDKK 428.4mDKK 159.5m91.1x91.1x33.9x
Fri, 28 Oct 2022DKK 12.5bDKK 428.4mDKK 159.5m78.1x78.1x29.1x
Sun, 25 Sep 2022DKK 10.8bDKK 428.4mDKK 159.5m67.7x67.7x25.2x
Tue, 23 Aug 2022DKK 14.6bDKK 358.0mDKK 131.3m111x111x40.7x
Thu, 21 Jul 2022DKK 13.6bDKK 358.0mDKK 131.3m103.3x103.3x37.9x
Sat, 18 Jun 2022DKK 13.0bDKK 358.0mDKK 131.3m99.1x99.1x36.3x
Mon, 16 May 2022DKK 11.7bDKK 358.0mDKK 131.3m89.2x89.2x32.7x
Wed, 13 Apr 2022DKK 15.6bDKK 358.0mDKK 131.3m118.8x118.8x43.6x
Fri, 11 Mar 2022DKK 13.2bDKK 358.0mDKK 131.3m100.2x100.2x36.7x
Sun, 06 Feb 2022DKK 11.7bDKK 281.1mDKK 88.4m132.5x132.5x41.6x
Tue, 04 Jan 2022DKK 14.1bDKK 281.1mDKK 88.4m159.3x159.3x50.1x
Thu, 02 Dec 2021DKK 16.0bDKK 281.1mDKK 88.4m181x181x56.9x
Sat, 30 Oct 2021DKK 16.6bDKK 281.1mDKK 88.4m191.4x187.9x59.1x
Mon, 27 Sep 2021DKK 19.0bDKK 281.1mDKK 88.4m215.1x215.1x67.6x
Wed, 25 Aug 2021DKK 16.7bDKK 243.5mDKK 74.0m225.7x225.7x68.6x
Price to Earnings Ratio

232.6x


Total Market Cap: DKK 17.2bTotal Earnings: DKK 74.0mTotal Revenue: DKK 243.5mTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Clinical Research and Equipment Industry Price to Earnings3Y Average 96.7x202220232024
Current Industry PE
    There are only 2 companies in the Danish Life Sciences Tools and Services industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 36% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Danish Clinical Research and Equipment compare with similar industries?

DK Market-1.01%
Healthcare-0.96%
Life Sciences-7.05%
Clinical Research and Equipment-7.05%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GUBRA GubraDKK 650.006.9%
+DKK 684.2m
618.2%PS51.7x
CHEMM ChemoMetecDKK 392.606.2%
+DKK 400.3m
-12.2%PE47.5x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

GUBRA

DKK 650.00

Gubra

7D

6.9%

1Y

618.2%

CHEMM

DKK 392.60

ChemoMetec

7D

6.2%

1Y

-12.2%